European Healthtech startup funding raised during Q2 2013.
In Q2 2013, 31 European Healthtech companies raised a combined €356M across 32 funding rounds, up 160.6% versus Q2 2012. Finland led by capital raised, and Lanzadera was the most active investor. Data as of 7 Aug 2026.
| Company | Stage | Date | Amount |
|---|---|---|---|
| Biotie Therapies | Grant | Jun 2013 | €111M |
| Symphogen | Growth/Late | May 2013 | €41M |
| Auris Medical | Series C | Apr 2013 | €40M |
| Opsona | Series C | Apr 2013 |
1 exit · €42M disclosed.
| Oxford Nanopore Technologies | Buyout | Jun 2013 | €42M |
| €33M |
| GenSight Biologics | Series A | Apr 2013 | €32M |
| STAT-Diagnostica | Series B | May 2013 | €22M |
| Genticel | Series D+ | Apr 2013 | €18M |
| Phagenesis | Series B | May 2013 | €15M |
| Treato | Series B | Apr 2013 | €11M |
| Dysis Medical | Early VC | Apr 2013 | €8.8M |
| Horizon Discovery | Series C | Jun 2013 | €8.1M |
| Sofinnova Partners | Other | Apr 2013 | €8.0M |
| Biocartis | Grant | Jun 2013 | €1.8M |
| InSphero | Series B | Jun 2013 | €1.6M |
| Minoryx Therapeutics | Series A | Apr 2013 | €1.5M |
